Treatment of Strongyloides stercoralis hyperinfection‐associated septic shock and acute respiratory distress syndrome with drotrecogin alfa (activated) in a renal transplant recipient
- 31 May 2009
- journal article
- case report
- Published by Wiley in Transplant Infectious Disease
- Vol. 11 (3) , 277-280
- https://doi.org/10.1111/j.1399-3062.2009.00386.x
Abstract
We report a case of Strongyloides stercoralis hyperinfection syndrome in a renal transplant recipient complicated by septic shock, acute respiratory distress syndrome, and Klebsiella pneumoniae superinfection. The patient was treated successfully with drotrecogin alfa (activated), parenteral ivermectin, albendazole, and piperacillin/tazobactam. This outcome suggests that drotrecogin alfa (activated) may be useful therapy for transplant recipients who develop severe sepsis or septic shock secondary to potentially lethal opportunistic infections.Keywords
This publication has 17 references indexed in Scilit:
- Banff 07 Classification of Renal Allograft Pathology: Updates and Future DirectionsAmerican Journal of Transplantation, 2008
- Drotrecogin alfa (activated) in severe falciparum malariaAnaesthesia, 2006
- Drotrecogin Alpha (Activated) in Two Patients with the Hantavirus Cardiopulmonary SyndromeCanadian Respiratory Journal, 2006
- Treatment of Human Disseminated Strongyloidiasis with a Parenteral Veterinary Formulation of IvermectinClinical Infectious Diseases, 2005
- A Novel Use for Drotrecogin Alfa (Activated): Successful Treatment of Septic Shock Associated with CoccidioidomycosisClinical Infectious Diseases, 2004
- Strongyloides stercoralisin the Immunocompromised PopulationClinical Microbiology Reviews, 2004
- Solid-organ transplant recipients treated with drotrecogin alfa (activated) for severe sepsisTransplantation, 2003
- Diagnosis ofStrongyloides stercoralisInfectionClinical Infectious Diseases, 2001
- Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of careCritical Care Medicine, 2001
- Efficacy and Safety of Recombinant Human Activated Protein C for Severe SepsisNew England Journal of Medicine, 2001